The activating mutation, BRAFV600E, is a frequent genetic event in papillary thyroid carcinomas (PTCs) that predicts poor prognosis, leading to loss of sodium/iodide symporter (NIS) expression and subsequent radio-iodide-refractory metastatic disease. This evidence concerns the gene SLC5A5 and metastatic neoplasm.